Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Key Points

• To review the treatment recommendations for bone-directed therapy in patients with neuroendocrine tumour skeletal metastases.
• Reviewed recommendations from the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting.
• Analyzed data from 29 meetings out of 365 total meetings.
• Evaluated the uptake of recommended therapies among patients.
• Bone-specific treatment recommendations were made in 7.9% of meetings.
• 44.8% of patients received the recommended therapy.
• Emphasized the infrequency of treatment recommendations and the need for further data.